CliffBio
small molecule

DILTZAC

DILTIAZEM HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameDILTZAC
Active ingredientDILTIAZEM HYDROCHLORIDE
Strength360MG
Dosage formCAPSULE, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 2006
Marketing statusDISCN

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.